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ABStRACt
Nasopharyngeal carcinoma of undifferentiated type is an endemic cancer with a high incidence in Southern 
China, Taiwan, and Singapore, followed by North African countries and Alaska. Despite intensive definitive 
treatment, regrettably about 30% of patients still suffer from loco-regional relapse or even distant metastasis. 
Palliative chemotherapy has been the standard treatment for those whose disease is not amenable to further 
radical surgery or a second course of radiotherapy. Though mainly given with palliative intent, this form of 
chemotherapy can achieve excellent symptom control and prolong survival. More recently targeted therapy 
has also been widely evaluated in metastatic nasopharyngeal carcinoma. Here we provide a comprehensive 
review on the use of various types of palliative chemotherapy and targeted therapy for recurrent and metastatic 
nasopharyngeal carcinoma by searching the MEDLINE and PubMed databases from 1980 to March 2013. 
The key words used were “nasopharyngeal”, “nasopharynx”, “recurrent”, “metastatic”, “chemotherapy”, 
“targeted therapy”, and “immunotherapy”.  
Key Words: Antineoplastic agents; Carcinoma; Nasopharyngeal neoplasms; Neoplasm recurrence, local; Radiotherapy, 
adjuvant
中文摘要
復發性和轉移性鼻咽癌的姑息性化療和靶向治療：回顧與前瞻
李浩勳、鄺麗雲
未分化型鼻咽癌是一種地方性癌症，在中國南部、台灣和新加坡的發病率偏高，其次為北非國家
和阿拉斯加。儘管施以針對性強化治療，仍然有約30%的患者遭受癌症局部復發甚至遠處轉移的
痛苦。對於那些不適合接受擴大根治性手術或第二療程放療的患者來說，姑息性化療一向是標
準的治療方法。雖然該形式的化療主要以姑息緩解為目的，卻可達到出色的症狀控制並延長生
存期。最近，以靶向治療醫治轉移性鼻咽癌被廣泛評估。我們檢索MEDLINE和PubMed數據庫中
1980年至2013年3月的相關文獻，全面回顧復發性和轉移性鼻咽癌的各種類型姑息性化療和靶向
治療的運用。使用的關鍵字為「鼻咽癌」（nasopharyngeal），「鼻咽部」（nasopharynx），「復
發」（recurrent），「轉移」（metastatic），「化療」（chemotherapy），「靶向治療」（targeted	
therapy）和「免疫治療」（immunotherapy）。
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iNtRODUCtiON
Undifferentiated	nasopharyngeal	 carcinoma	 (NPC)	 is	
an	endemic	cancer	with	a	high	 incidence	 in	Southern	
China,	Taiwan,	 and	Singapore,	 and	a	 lower	 incidence	
in	North	African	countries	 and	Alaska.	Radiotherapy	
is	 the	mainstay	of	 treatment	 for	 early	 stage	NPC,	
while	 concurrent	 chemoradiation	 is	 indicated	 for	
locoregionally	 advanced	disease,	 as	 revealed	by	
previous	phase	 III	 randomised	controlled	 trials	 and	a	
recent	meta-analysis.1	Nevertheless,	about	30%	of	cases	
relapse	 locoregionally	or	distantly,	despite	 intensive	
definitive	 treatment.2	Though	most	of	 these	 relapsed	
patients	have	an	unfavourable	 survival	outcome,	 their	
survival	 can	be	 significantly	prolonged	with	palliative	
chemotherapy	and	more	 recently	 targeted	 therapy	has	
demonstrated	encouraging	objective	 responses	and	
treatment	outcomes.	In	this	article,	we	comprehensively	
review	 the	previous	 literature	on	 the	use	of	palliative	
chemotherapy	and	comment	on	 the	use	of	 targeted	
therapy	and	other	novel	future	 treatments	for	recurrent	
and	metastatic	NPC.
MEtHODS
MEDLINE	and	PubMed	databases	were	 searched	
from	1980	 till	March	2013.	Key	words	 including	
“nasopharyngeal”,	 “nasopharynx”,	 “recurrent”,	
“metastatic”,	 “chemotherapy”,	 “targeted	 therapy”,	 and	
“immunotherapy”	were	used	for	the	literature	search.
PAlliAtivE CHEMOtHERAPy
Although	well	 established	as	 a	 standard	 treatment	 for	
metastatic	NPC,	 there	have	been	no	 randomised	 trials	
comparing	efficacy	of	different	 chemotherapeutic	
regimens	and	no	evidence	pertaining	 to	prolongation	
of	 survival	 compared	 to	 best	 supportive	 care.3	
Apart	 from	 that,	quality-of-life	 assessment	during	
chemotherapy	 is	often	 ignored	 in	 these	 retrospective	
or	phase	 II	 studies.	Moreover,	 the	majority	are	 small-
scale	 studies	 that	 are	 inherently	difficult	 for	 the	
purpose	of	meaningful	 comparison	between	different	
chemotherapy	regimens.	In	summary,	these	trials	can	be	
categorised	 into	monotherapy,	doublet	 chemotherapy,	
and	polychemotherapy	 studies	used	 in	chemo-naïve	
patients	or	those	who	have	received	prior	chemotherapy	
for	recurrent	/	metastatic	disease.	
Monotherapy
Anecdotal	 reports	have	demonstrated	 that	 the	use	of	
older	agents	like	methotrexate,	bleomycin,	5-fluorouracil	
(5-FU),	 epidoxorubicin,	mitoxantrone,	 and	platinum	
compounds	produce	a	 response	 rate	between	15	and	
30%.3-5	More	 recent	 clinical	 trials	have	 investigated	
the	efficacy	of	newer	agents	 including	gemcitabine,	
irinotecan,	paclitaxel,	capecitabine,	and	docetaxel	(Table	
1).5-14	Notably,	gemcitabine	and	capecitabine	are	 the	
foci	of	recent	studies,	offering	a	response	rate	between	
24	and	48%	and	median	progression-free	survival	(PFS)	
between	4	and	14	months.8-13	Docetaxel,	 as	 a	 single	
agent,	 also	produced	a	 response	 rate	of	37%	and	a	
median	PFS	of	5	months.14
Doublet Chemotherapy
Platinum	doublets	 are	 regarded	 as	 the	 principal	
treatment	modality	 for	medically	 fit	patients	with	
metastatic	NPC.	Clinical	 trials	 entailing	platinum	
doublets	have	exhibited	 response	 rates	 from	20	 to	
Author(s) Study No. of patients Regimen OR rate 
(%)
CR rate 
(%)
Median PFS Median OS
Dugan et al5 Ph II 108 R + M pretreated Mitoxantrone 25 NR 4.5 months 13 months
Au et al6 Ph II 24 M untreated Paclitaxel 21.7 0 7.5 months 12 months
Poon et al7 Ph II 28 M pretreated Irinotecan 14 0 3.9 months 11.4 months
Foo et al8 Ph II 25 M pretreated
27 M untreated
Gemcitabine 28
48
4
3.7
3.6 months
5.1 months
7.2 months
10.5 months
Ma et al9 Retrospective 18 R + M untreated 
and pretreated
Gemcitabine 34 6 31% (1 month) 48% (1 year)
Chua et al10 Ph II 17 R + M pretreated Capecitabine 23.5 5.9 4.9 months 7.6 months
Chua et al11 Retrospective 49 R + M pretreated Capecitabine 37 6 5 months 14 months; 
54% (1 year)
Ciuleanu et al12 Ph II 26 R + M pretreated Capecitabine 48 9 14 months 62% (1 year)
Zhang et al13 Ph II 32 pretreated Gemcitabine 43.8 0 5.1 months 16 months; 
63% (1 year)
Ngeow et al14 Ph II 30 R + M pretreated Docetaxel (weekly) 37 0 5.3 months 12.8 months
Table 1. Monochemotherapy in recurrent and / or metastatic nasopharyngeal carcinoma with or without pretreatment.
Abbreviations: CR = complete response; M = metastatic; NR = not reported; OR = objective response; OS = overall survival;  
PFS = progression-free survival; Ph II = phase II; R = recurrent.
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76%;	one	study	showed	that	all	patients	with	recurrent	
disease	only	 responded	 to	cisplatin	and	5-FU	 (Table	
2).9,15-36	Platinum	and	5-FU	combination	 therapy	 is	 the	
most	popular	among	doublet	regimens	widely	practised	
in	Asian	countries	where	 the	disease	 is	 endemic.	The	
dose	of	 cisplatin	 is	100	mg/m2	on	day	1	and	 that	 for	
5-FU	 is	1000	mg/m2	over	3	 to	5	days,	given	every	
3	weeks.	This	popular	 regimen	produced	an	overall	
response	(OR)	rate	between	66	and	78%	and	a	median	
survival	of	12	 to	14	months.15-17	In	particular,	Chi	 et	
al17	 revealed	 that	 all	patients	with	 locally	 recurrent	
disease	 responded	 to	cisplatin,	5-FU	and	 leucovorin	
producing	a	median	 survival	of	34	months,	while	
80%	of	 those	with	metastatic	disease	 responded	with	
a	median	 survival	of	14	months.	This	 regimen	was	
found	effective	even	in	patients	who	had	received	prior	
chemotherapy.	All	five	patients	who	had	earlier	received	
mitoxantrone	still	responded,	suggesting	a	lack	of	cross-
resistance.	Another	 four	patients	with	good	 responses	
to	prior	 induction	chemotherapy	with	cisplatin	and	
5-FU	 followed	by	 radiotherapy	who	 then	developed	
metastatic	disease	with	disease-free	 intervals	greater	
than	1	year	 still,	 nevertheless,	 responded	 to	 the	 same	
regimen.17	Moreover,	 the	 toxicity	profile	 is	generally	
favourable	with	mild	immunosuppression	and	peripheral	
neuropathy.	However	cisplatin-induced	nephrotoxicity	
and	ototoxicity	were	of	 concern,	 especially	 in	patients	
who	had	also	 received	cisplatin	during	 their	previous	
definitive	chemoradiation.	Commonly,	 carboplatin	
has	been	used	as	a	substitute	of	cisplatin	for	advanced	
head	and	neck	cancers	 including	NPC.37	Two	older	
randomised	controlled	 studies	on	advanced	head	and	
neck	cancers	demonstrated	that	cisplatin	was	superior	to	
carboplatin	in	terms	of	improved	response	rate.38,39	One	
of	 these	 showed	cisplatin	conferred	 superior	disease-
free	 survival	 and	overall	 survival	 (OS)	compared	 to	
carboplatin	when	both	were	used	with	5-FU.39	However	
this	 study	did	not	 recruit	patients	with	 recurrent	or	
metastatic	diseases.	More	recently,	carboplatin	has	been	
tested	with	concurrent	chemoradiation	against	cisplatin-
based	concurrent	 chemoradiation	 in	a	 randomised	
controlled	non-inferiority	 study.40	Patients	with	 locally	
advanced	NPC	were	 randomised	 to	 receive	cisplatin	
chemoradiation	versus	carboplatin	chemoradiation	
followed	by	adjuvant	 chemotherapy	using	 the	 same	
platinum	compound	as	in	the	concurrent	phase	coupled	
with	5-FU.	No	difference	in	3-year	disease-free	survival	
(p	=	0.9613)	and	OS	 (p	=	0.9814)	was	demonstrated.	
Author(s) Study No. of 
patients
Regimens OR rate 
(%)
CR rate 
(%)
Median PFS Median OS
Wang and Tan15 Retrospective 25 M Cisp + 5-FU 76 8 NR NR
Au and Ang16 Ph II 24 R + M Cisp + 5-FU 66 13 8 months 11 months
Chi et al17 Ph II 20 R
15 M
Cisp + 5-FU / LV 100
80
15
13
NR
NR
34 months
14 months
Stein et al18 Ph II 18 R + M Cisp + Ifos 59 15 NR NR
Yeo et al19 Ph II 42 M Carbo + 5-FU 38 17 NR 12.1 months
Yeo et al20 Ph II 27 R + M Carbo + Pac 59 11 6 months 13.9 months
Tan et al21 Ph II 32 M Carbo + Pac 75 3 7 months 12 months
Ciuleanu et al22 Ph II 40 M Carbo + Pac 27.5 7.5 3.5 months 11.5 months
Ngan et al23 Ph II 44 R + M Cisp + Gem 73 20 10.6 months 15 months
Ma et al9 Ph II 14 R + M Cisp + Gem 64 14 13% (1 year) 68% (1 year)
Wang et al24 Retrospective 75 R + M Cisp + Gem 42.7 5.3 5.6 months 9 months
Ma et al25 Ph II 40 R + M Oxali + Gem 56.1 0 9 months 19.6 months
McCarthy et al26 Ph II 9 R + M Cisp + Doc 22 0 8.4 months 76% (1 year)
Chua et al27 Ph II 19 M Cisp + Doc 62.5 6.3 5.6 months 12.4 months
Li et al28 Ph II 48 M Cisp + Cape 62.5 6.3 7.7 months 13.3 months
Chua et al29 Ph II 18 R + M Ifos + 5-FU / LV 56 6 6.5 months 51% (1 year)
Huang et al30 Ph II 34 R + M Ifos + Doc 67.6 14.7 6 months NR
Altundag et al31 Ph II 21 R + M Ifos + Doc 33.3 0 7 months NR
Wang et al32 Ph II 39 M Gem + Vino 36 3 5.6 months 11.9 months
Dede et al33 Retrospective 30 R + M Ifos + Doxo 30 0 4 months (median TTP) NR
Chen et al34 Ph II 61 R + M Gem + Vino 37.7 1.6 5.2 months 14.1 months
Yau et al35 Ph II 15 R + M Cisp + Pem 20 7 30 weeks (median TTP) NR
Chua et al36 Ph II 44 M Cisp + Cape 53.8 2.6 7.3 months (median TTP) 28.0 months
Table 2. Doublet chemotherapy regimens in recurrent and / or metastatic nasopharyngeal carcinoma with or without pretreatment.
Abbreviations: Cape = capecitabine; Carbo = carboplatin; Cisp = cisplatin; CR = complete response; Doc = docetaxel; Doxo = doxorubicin; 
5-FU = 5-fluorouracil; Gem = gemcitabine; Ifos = ifosphamide; LV = leucovorin; M = metastatic; NR = not reported; OR = objective response; 
OS = overall survival; Oxali = oxaliplatin; Pac = paclitaxel; Pem = pemetrexed; PFS = progression-free survival; Ph II = phase II; R = recurrent; 
TTP = time to progression; Vino = vinorelbine.
VHF	Lee	and	DLW	Kwong
Hong	Kong	J	Radiol.	2013;16:252-60	 255
In	2013,	 a	 retrospective	Malaysian	 study	compared	
cisplatin	and	5-FU	with	carboplatin	and	5-FU	 in	41	
patients	with	 recurrent	 and	metastatic	 squamous-cell	
head	and	neck	cancer	 and	NPC.41	This	 showed	 that	
carboplatin	and	5-FU	(median	survival,	12	months)	was	
not	 inferior	 to	cisplatin	and	5-FU	(median	survival,	10	
months;	p	=	0.110).	However,	drawbacks	of	this	study	
were	 that	no	 subgroup	analysis	was	performed	 for	
NPC	patients	only	and	there	were	six	treatment-related	
mortalities	 (14.6%)	—	four	 in	 the	carboplatin	+	5-FU	
group	and	two	in	the	cisplatin	+	5-FU	group.
Other	 active	 agents	 for	 recurrent	 and	metastatic	
NPC	 include	gemcitabine,	 capecitabine,	oxaliplatin	
and	 taxanes.42	One	 study	published	 in	2002	 tested	
gemcitabine	with	platinum	as	 first-line	chemotherapy	
for	metastatic	NPC	 in	44	patients	 and	was	carried	out	
in	Hong	Kong.23	 It	 showed	an	OR	 rate	of	73%	and	a	
median	PFS	of	11	months.	Gemcitabine	 together	with	
oxaliplatin	(a	third-generation	platinum	compound)	was	
also	evaluated.	This	Hong	Kong	multicentre	study	found	
that	first-line	gemcitabine	and	oxaliplatin	produced	an	
OR	of	57%	and	a	median	PFS	of	9	months.25	Use	of	
gemcitabine	with	a	non-platinum	compound	 in	NPC	
patients	pretreated	with	platinum	was	also	found	 to	be	
feasible.	A	Chinese	 study	 including	patients	 all	with	
disease	progression	while	 still	 on	previous	platinum-
based	chemotherapy	demonstrated	an	OR	 rate	of	36%	
and	median	PFS	of	6	months	after	gemcitabine	and	
vinorelbine.32	Another	Chinese	 study,	 in	which	about	
15%	of	61	patients	had	disease	progression	while	 still	
on	platinum-based	chemotherapy,	demonstrated	an	OR	
rate	of	38%,	and	a	median	PFS	of	5	months;	 and	 the	
median	OS	being	14	months	 following	 treatment	with	
a	median	of	4	cycles	of	gemcitabine	and	vinorelbine.34	
Use	of	 capecitabine,	 an	oral	pro-drug	of	5-FU,	 in	
combination	with	cisplatin	as	 first-line	 treatment	was	
also	evaluated.	Chua	et	 al36	published	a	multicentre	
study	on	such	 treatment	 in	44	patients	with	previously	
untreated	metastatic	NPC.	Of	the	39	patients	evaluable	
for	efficacy,	the	OR	rate	was	54%	including	one	patient	
(3%)	 showing	a	complete	 response.	The	median	 time	
to	progression	was	7	months	and	 the	median	OS	was	
28	months.	In	addition,	this	study	specially	emphasised	
quality-of-life	 assessment	using	FACT-G	and	disease-
specific	FACT-H&N	questionnaires.36	These	authors	
described	mild	decline	 in	quality-of-life	 scores	after	
chemotherapy,	which	was	 likely	due	 to	 side-effects	
and	 hospitalisation.	Docetaxel	 and	 ifosphamide	
doublet	 chemotherapy	 regimens	were	also	extensively	
studied.27,28,30,31	When	used	with	platinum	or	non-
platinum	compounds,	OR	 rates	were	between	22	and	
68%	and	median	PFS	ranged	between	6	and	8	months.
Most	recently	a	Hong	Kong	study	investigated	the	role	
of	pemetrexed	 (a	multi-targeted	5-FU	analogue)	when	
combined	with	cisplatin	 for	patients	with	 recurrent	or	
metastatic	NPC.35	When	used	with	 regular	 folic	 acid	
and	vitamin	B12	 supplements,	pemetrexed	per	 se	has	
very	 limited	 treatment-related	 side-effects.	Fifteen	
patients	were	 recruited	 into	 this	 study,	 six	of	whom	
had	 locoregional	 recurrence	while	 the	 rest	had	distant	
metastases	with	or	without	 locoregional	 recurrence.	
Three	patients	were	previously	 treated	with	cisplatin-
based	chemotherapy	as	prior	 first-line	 therapy,	while	
the	 rest	 received	cisplatin	during	 their	 initial	definitive	
chemoradiation.	Serum	biochemistry	 for	Epstein-Barr	
virus	 (EBV-DNA)	was	also	monitored	as	 a	 surrogate	
tumour	marker.	The	OR	rate	was	20%	and	one	patient	
(7%)	enjoyed	complete	 remission.	Another	 eight	
patients	 (53%)	had	 their	disease	 stabilised,	giving	
an	overall	 clinical	benefit	 rate	of	73%;	 three	patients	
(21%)	had	undetectable	EBV-DNA	after	 treatment.	
Pemetrexed	was	well-tolerated;	only	one	patient	who	
had	grade	4	 anaemia.	The	most	 common	grade	3	
toxicities	 included	neutropenia	 (27%)	and	anaemia	
(20%).	No	patient	developed	 febrile	neutropenia	after	
treatment.	As	persistent	 and	 irreversible	 treatment-
related	 toxicity	often	precludes	 long-term	use	of	
chemotherapy,	 it	 is	hoped	 that	 combination	 regimens	
with	such	new	agents	can	offer	durable	disease	control	
and	at	the	same	time	minimise	toxicities.
It	is	still	under	hot	debate	whether	patients	can	be	safely	
re-challenged	with	cisplatin	 if	 they	were	exposed	 to	
it	during	previous	 induction	chemotherapy,	definitive	
cisplatin-based	chemoradiation	or	prior	palliative	
chemotherapy.	An	older	 study	 revealed	 that	 all	 four	
patients	with	a	disease-free	interval	of	more	than	1	year	
after	 induction	cisplatin	and	5-FU	and	 radiotherapy	
still	 responded	 to	 the	 same	 regimen.17	 In	 their	 study	
on	doublet	 regimen	using	cisplatin	and	capecitabine	
for	previously	untreated	metastatic	NPC,	Chua	et	
al36	demonstrated	 that	prior	 adjunctive	 (neoadjuvant,	
concurrent,	or	 adjuvant)	 chemotherapy	given	at	 least	
6	months	before	 study	entry	had	a	 longer	PFS	 (9	vs.	
7	months)	 and	OS	 (30	vs.	28	months),	 though	 the	
differences	were	not	 statistically	 significant.	Recently,	
molecular	medicine	has	played	an	 important	 role	 in	
the	prediction	of	 chemosensitivity.	Some	 light	has	
been	 shed	on	 the	discovery	of	 excision	 repair	 cross	
complementation	group	1	 (ERCC1)	and	xeroderma	
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pigmentosum	complementation	group	F	(XPF)	involved	
in	 the	 repair	 cisplatin-DNA	adducts	via	different	
pathways.	These	have	a	bearing	on	 the	nucleotide	
excision	 repair	pathway,	double-strand	break	 repair,	
and	repair	of	interstrand	crosslinks.43-48	When	associated	
with	 ERCC1,	XPF	 forms	 a	 heterodimer	which	
functions	as	 a	 structure-specific	 endonuclease.	The	
ERCC1	also	binds	and	stabilises	XPF,	which	enhances	
the	 latter’s	 endonuclease	 to	create	an	 incision	5’	 to	
the	DNA	 lesion,	 thus	allowing	DNA	 to	be	 repaired.	
Four	 studies	confirmed	 that	high	expression	 levels	of	
ERCC1	conferred	poor	 treatment	outcomes	 in	NPC	
when	cisplatin	was	administered	as	induction	treatment,	
concurrently	with	 radiation	 therapy	or	palliative	
setting.43-46	Another	 study	 showed	 that	high	ERCC1	
levels	predicted	poor	 locoregional	 control,	but	did	
not	predict	 resistance	 to	cisplatin.47	One	more	 recent	
study	 showed	 that	neither	ERCC1	nor	XPF	predicted	
locoregional	 recurrence,	disease-free	 survival	 and	OS	
in	142	patients	with	NPC	treated	with	curative	intent.48	
Perhaps	one	of	the	solutions	to	these	conflicting	results	
is	 to	 re-biopsy	 the	 recurrent	 /	metastatic	 lesions	 to	
evaluate	chemosensitivity	to	platinum.
Overall,	all	 these	published	trials	should	be	interpreted	
with	great	caution,	due	to	small	sample	sizes,	the	nature	
of	phase	 II	 studies,	patient	population	heterogeneity	
(locoregional	 recurrence	alone	vs.	distant	metastasis),	
and	variations	 in	prior	 lines	of	systemic	chemotherapy	
(especially	 if	platinum-based).	Notwithstanding	 the	
limitations	of	 these	clinical	 and	molecular	 studies,	we	
recommend	cisplatin,	preferably	with	5-FU,	as	 the	
first	choice	due	to	the	long	history	and	experience	with	
these	agents,	especially	for	chemo-naïve	patients.	When	
length	of	hospital	 stay	becomes	an	 issue,	5-FU	may	
be	 substituted	by	newer	agents	 such	as	 capecitabine,	
gemcitabine,	and	taxanes.	For	second-line	or	subsequent	
treatment	of	metastasis,	whether	platinum-based	
chemotherapy	was	given	previously	is	a	consideration.	
For	patients	treated	with	platinum-based	chemotherapy,	
subsequent	 treatment	depends	on	performance	 status,	
toxicity,	 and	 the	 interval	 to	 recurrence	after	previous	
platinum-based	 regimen.	Re-challenge	with	cisplatin	
and	5-FU	can	be	considered	 in	patients	who	enjoyed	
a	good	 initial	 response	 to	 the	 same	 regimen	with	an	
intervening	disease-free	period	of	more	 than	1	year.	
Carboplatin	 is	 an	acceptable	 substitute	producing	
similar	 responses	and	outcomes	when	cisplatin	 is	
contraindicated,	 though	 it	generally	gives	 rise	 to	more	
haematological	toxicities.	For	patients	who	fail	platinum	
and	5-FU	or	whose	disease	relapse	within	a	year	of	such	
a	regimen,	second-line	treatment	including	gemcitabine,	
capecitabine,	or	 taxanes	with	or	without	platinum	can	
be	considered.	
Polychemotherapy
Use	of	more	than	doublet	combination	chemotherapy	has	
not	been	shown	to	be	superior	to	doublet	counterparts.	
Several	 trials	 reported	on	 the	polychemotherapy	 for	
recurrent	NPC	and	demonstrated	encouraging	response	
rates	but	 also	more	 treatment-related	 toxicities	 (Table	
3).49-56	More	importantly,	they	have	not	been	compared	
with	 the	 standard	5-FU	+	cisplatin	doublet	 regimen.	
One	 study,	CAPABLE,	 incorporating	 five	compound	
(cisplatin,	methotrexate,	bleomycin,	cyclophosphamide,	
and	doxorubicin),	was	associated	with	a	response	rate	of	
80%	but	 also	an	extraordinarily	high	 treatment-related	
mortality	of	12%.52	Another	phase	II	study,	using	5-FU,	
mitomycin,	 epirubicin,	 and	cisplatin	demonstrated	a	
response	rate	of	52%	at	the	expense	of	iatrogenic	death	
of	9%.54	In	general,	polychemotherapy	entailing	three	or	
more	agents	is	not	routinely	recommended.
Author(s) Study No. of patients Regimens OR (%) CR (%) Median PFS Median OS
Boussen et al49 Ph II 49 R + M untreated and 
pretreated 
Cisp + B + 5-FU 79 19 50 months NR
Su et al50 Ph II 25 R + M Cisp + B + 5-FU 40 3 NR NR
Azli et al51 Ph II 44 R + M pretreated and not BEC (B + Epi + Cisp) 45 20 53 months NR
Siu et al52 Ph I / II 17 R
44 M
CAPABLE 41
80
23.5
6.8
NR
NR
16 months
14 months
Taamma et al53 Ph II 23 R + M FBEC (5-FU + B + Epi + Cisp) 78 39 42 months NR
Hasbini et al54 Ph II 44 R + M FMEP (5-FU + mitomycin + Epi 
+ Cisp)
52 13 9 months 14 months
Leong et al55 Ph II 28 M Carbo + Gem + Pac + 5-FU / LV 86 11 8 months 22 months
Huang et al56 Ph II 56 R + M DCF (Doc + Cisp + 5-FU) 72.5 9.8 NR NR
Table 3. Results for polychemotherapy in recurrent and / or metastatic nasopharyngeal carcinoma with or without pretreatment.
Abbreviations: B = bleomycin; CAPABLE: Cyclophospamide + Bleomycin + Doxorubicin + Cisplatin; Carbo = carboplatin; Cisp = cisplatin; CR 
= complete response; Doc = docetaxel; Epi = epirubicin; 5-FU = 5-fluorouracil; Gem = gemcitabine; Ifos = ifosphamide; LV = leucovorin; M = 
metastatic; NR = not reported; OR = objective response; OS = overall survival; Pac = paclitaxel; PFS = progression-free survival; Ph II = phase 
II; R = recurrent.
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PAlliAtivE tARgEtED tHERAPy
A	number	of	studies	have	tested	the	efficacy	of	targeted	
therapy	 for	metastatic	NPC.	First	of	 all,	 like	other	
squamous-cell	 head	and	neck	cancers,	 epidermal	
growth	factor	receptor	(EGFR)	is	also	highly	expressed	
in	NPC.57-59	Thus,	 a	 few	studies	 investigated	 the	 role	
of	EGFR	 tyrosine	kinase	 inhibitors	 and	monoclonal	
antibodies	 in	metastatic	NPC.	A	small	phase	 II	 study	
from	Hong	Kong	showed	 that	none	of	19	patients	
responded	after	gefitinib	in	previously	heavily	pretreated	
NPC,	with	median	values	 for	 time	 to	progression	and	
OS	of	4	and	16	months,	 respectively.60	Another	Hong	
Kong	study	was	 terminated	due	 to	 lack	of	 efficacy	
following	 treatment	with	gefitinib.61	Likewise,	 a	phase	
II	study,	using	erlotinib	as	maintenance	treatment	after	
6	cycles	of	gemcitabine	and	cisplatin	 in	chemo-naïve	
patients	with	metastatic	NPC,	revealed	stable	disease	in	
only	three	out	of	12	evaluable	patients.62	Thus,	erlotinib	
appeared	 to	be	no	better	 than	geftinib	 in	metastatic	
NPC.	Use	of	cetuximab,	a	monoclonal	antibody	against	
EGFR,	 in	 combination	with	 carboplatin	was	also	
tested.	Seven	(12%)	out	of	59	patients	enjoyed	a	partial	
response	with	a	median	PFS	of	3	months	and	median	
OS	of	8	months,	but	 at	 the	expense	of	 significant	
toxicity	(grade	≥3	toxicities	in	52%	of	the	patients).63
Vascular	 endothelial	growth	 factor	 (VEGF)	and	 its	
receptor	(VEGFR)	is	also	a	potential	target	of	treatment	
in	NPC.	Its	overexpression	was	found	in	60	to	67%	of	
patients	 and	also	conferred	a	 shorter	 survival.64,65	The	
use	of	 sorafenib,	 an	oral	multikinase	 inhibitor,	was	
also	not	 shown	 to	be	more	efficacious	 than	 systemic	
chemotherapy.66	A	more	 recently	published	phase	
II	 study	on	 sorafenib	 in	combination	with	 standard	
cisplatin	and	5-FU	 regimen	 in	 the	 induction	phase	
followed	by	maintenance	 sorafenib	until	 disease	
progression	demonstrated	a	high	 response	 rate	of	78%	
and	median	PFS	of	7	months	and	median	OS	of	12	
months.67	However,	this	regimen	was	also	accompanied	
by	a	high	 frequency	of	hand-foot-skin	 reactions	 (83%	
in	all	 and	19%	 in	grade	≥3),	 leucopenia	 (78%	 in	all	
and	7%	in	grade	≥3),	and	haemorrhagic	events	(22%	in	
all	 and	2%	 in	grade	≥3).	Another	multikinase	 tyrosine	
kinase	 inhibitor	 sunitinib	was	also	 tested	 in	metastatic	
NPC	in	Hong	Kong.68	Of	the	10	patients	who	had	post-
treatment	radiological	assessment	for	tumour	response,	
one	patient	had	a	partial	 response	and	another	 three	
remained	stable	for	at	least	12	months.	Meanwhile,	the	
haemorrhagic	events	also	deserve	attention	(64%	in	all,	
29%	 in	grade	3/4,	 and	14%	 in	grade	5)	 and	 included	
epistaxis,	haemoptysis,	 and	haematemesis	 in	6,	3,	 and	
2	patients,	 respectively.	Two	patients	with	 tumour	
invasion	 to	 the	carotid	sheath	suffered	a	fatal	epistaxis	
/	haematemesis	which	was	 likely	 secondary	 to	carotid	
blowout	after	 tumour	 shrinkage.	Pazopanib,	 another	
orally	available	multikinase	inhibitor	against	VEGFR-1,	
-2,	 and	 -3,	platelet-derived	growth	 factor	 (PDGF)-α,	
PDGF-β	and	c-kit	 tyrosine	kinases	was	also	evaluated	
in	NPC.69	Two	(6%)	out	of	33	patients	enjoyed	a	partial	
response	and	another	16	 (48%)	patients	had	 stable	
disease.	Treatment	was	 fairly	 tolerated;	 fatigue	and	
hand-foot	 syndrome	were	 the	commonest	grade	≥3	
toxicities.	One	patient	died	of	epistaxis	and	myocardial	
infarction.	At	 around	 the	 same	 time,	bevacizumab,	 an	
anti-angiogenic	monoclonal	 antibody,	was	also	 shown	
to	produce	promising	 responses	when	combined	with	
cisplatin	chemoradiation	as	 the	definite	 treatment	
for	 locally	advanced	NPC.70	Whether	 the	effect	of	
bevacizumab	and	 systemic	chemotherapy	can	also	
accrue	 in	a	metastatic	 setting	will	depend	on	 results	
from	future	studies.
New	genes	and	 /	or	growth	 factor	pathways	have	
been	 identified	as	potential	 targets	of	new	 targeted	
therapies.	For	 instance,	 the	PI3K/Akt	pathway	was	
recently	 revealed	 to	be	 frequently	 involved	 in	NPC	
tumourigenesis	 and	 progression.71,72	Apart	 from	
that,	microRNAs	 (miRNAs),	 a	diverse	class	of	20-
24–nucleotide	non-coding	RNAs	were	also	 found	
upregulated	 in	NPC	compared	with	non-tumorous	
nasopharyngeal	 tissues.73-78	A	 local	 study	 found	 that	
upregulation	of	miRNA-144	promoted	malignant	
progression	by	 repressing	 the	expression	of	 a	 tumour	
suppressor	gene	phosphatase	and	 tensin	homologue	
(PTEN),	which	is	partially	responsible	for	upregulation	
of	 the	PI3K/Akt	pathway	 in	NPC.65	 In-vitro	cell-line	
studies	have	demonstrated	 that	Akt	 inhibitors	 can	
suppress	tumour	growth.	Hopefully	the	efficacy	of	these	
inhibitors	 can	be	 further	verified	 in	phase	 II	 and	 III	
clinical	trials.79,80
CONClUSiON
In	 summary,	 a	platinum-based	chemotherapy	 regimen	
especially	cisplatin	and	5-FU	is	still	 the	principal	first-
line	treatment	for	recurrent	/	metastatic	NPC.	Cisplatin	
is	preferred	over	 carboplatin	based	on	 its	 long	history	
with	much	accumulated	experience	by	oncologists.	
However,	other	 factors	 including	 the	 toxicity	profile	
of	 chemotherapy,	 renal	 function,	 and	 length	of	 stay	 in	
hospital	 for	protracted	5-FU	 infusions	 should	be	 taken	
into	account	when	considering	 this	 regimen.	Newer	
chemotherapeutic	agents	like	gemcitabine,	capecitabine	
Recurrent	and	Metastatic	Nasopharyngeal	Carcinoma
258	 Hong	Kong	J	Radiol.	2013;16:252-60
and	 taxanes	can	be	 safely	combined	with	platinum	
compounds	either	as	first-line	or	subsequent-line	therapy	
to	 substitute	 for	5-FU,	especially	when	hospitalisation	
is	 a	major	 concern.	Combination	chemotherapy	using	
three	or	more	agents	has	not	been	 shown	superior	
to	doublet	 regimens.	The	 role	of	 targeted	 therapy	 in	
NPC	 is	 still	 evolving.	New	 targets	 and	growth	 factor	
pathways	have	been	gradually	 identified	and	new	
compounds	against	 these	 targets	 are	awaited.	Current	
attention	 is	 also	 focused	on	 immunotherapy,	using	
autologous	EBV-specific	 cytotoxic	T-lymphocytes	
(CTLs)	targeting	the	antigens	of	EBV	including	EBNA-
1,	 latent	membrane	protein-1	 (LMP-1)	and	 latent	
membrane	protein-2	(LMP-2).81,82	Previous	pilot	studies	
have	demonstrated	 that	CTL	 immunotherapy	 is	well	
tolerated	without	 any	 immunosuppressive	effects	on	
bone	marrow	as	 seen	 in	chemotherapy.83-87	One	pilot	
study	conducted	by	Secondino	et	al86	showed	an	OR	rate	
of	27%	and	disease	control	rate	of	55%	in	a	series	of	11	
patients.	Preliminary	results	of	using	a	novel	adenoviral	
vector-based	vaccine	 (AdE1-LMPoly)	 that	 encodes	
multiple	CTL	epitones	from	LMP1	and	LMP2	are	also	
promising.87	With	all	 these	novel	 ideas	and	 treatment	
options,	we	anticipate	a	new	paradigm	of	 systemic	
treatment	for	metastatic	NPC	in	the	near	future.
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